单药治疗失败后强化治疗时机与后续血糖控制的关系:93,515例2型糖尿病患者分析
该回顾性分析基于英国临床实践研究数据链数据库,纳入93,515例二甲双胍或磺脲类单药治疗≥3个月后HbA1c≥7%(≥53 mmol/mol)的2型糖尿病患者,评估强化治疗时机与后续血糖控制的关系。结果显示,与早期强化(<12个月)相比,中期(12至<24个月)和晚期(24至<36个月)强化患者达到血糖控制的可能性分别低22%和28%(P<0.0001)。结论认为,更早的强化治疗与更短的后续血糖控制时间相关。
要点
- 单药失败后早期强化(<12个月)者达到HbA1c<7%的中位时间为20.0个月,中期和晚期分别为24.1和25.7个月。
- 与早期强化相比,中期和晚期强化患者达到血糖控制的可能性分别低22%和28%(P<0.0001)。
- 研究纳入93,515例患者,其中25%在12个月内强化,13%在12至<24个月强化,8%在24至<36个月强化。
核心结论
- 更早的治疗强化与更短的后续血糖控制时间相关,且独立于一线治疗是二甲双胍还是磺脲类。
研究设计与样本
- 回顾性分析英国临床实践研究数据链数据库,纳入93,515例2型糖尿病患者,平均年龄60岁,约59%男性,80%使用二甲双胍。
主要发现
- 早期强化(<12个月)组达到血糖控制的中位时间为20.0个月,中期(12至<24个月)组为24.1个月,晚期(24至<36个月)组为25.7个月。
- 调整基线差异后,与早期强化组相比,中期强化组达到血糖控制的可能性低22%,晚期强化组低28%(P<0.0001)。
关键数值与推荐
- 强化治疗定义为在索引日期后起始一种或多种非胰岛素降糖药联合二甲双胍或磺脲类。
- 血糖控制定义为强化治疗后首次HbA1c<7%(<53 mmol/mol)。
- 早期强化:<12个月;中期强化:12至<24个月;晚期强化:24至<36个月。
临床怎么用
- 对于二甲双胍或磺脲类单药治疗失败且HbA1c≥7%的2型糖尿病患者,较早启动强化治疗与更短的血糖控制达标时间相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The goal of this study was to evaluate the association between the timing of treatment intensification and subsequent glycemic control among patients with type 2 diabetes in whom monotherapy fails. RESEARCH DESIGN AND METHODS: This retrospective analysis of the U.K. Clinical Practice Research Datalink database focused on patients with type 2 diabetes and one or more HbA1c measurements ≥7% (≥53 mmol/mol) after ≥3 months of metformin or sulfonylurea monotherapy (first measurement meeting these criteria was taken as the study index date). Baseline (6 months before the index date) characteristics were stratified by time from the index date to intensification (early: <12 months; intermediate: 12 to <24 months; late: 24 to <36 months). Intensification was defined as initiating after the index date one or more noninsulin antidiabetes medication in addition to metformin or a sulfonylurea. Association between time to intensification and subsequent glycemic control (first HbA1c <7% [<53 mmol/mol] after intensification) was evaluated using Kaplan-Meier analyses and Cox proportional hazard models that accounted for baseline differences. RESULTS: Of the 93,515 patients who met the study criteria (mean age 60 years; ∼59% male; 80% taking metformin), 23,761 (25%) intensified <12 months after the index date; 11,908 (13%) intensified after 12 to <24 months; and 7,146 (8%) intensified after 24 to <36 months. Patients who intensified treatment ≥36 months after the index date (n = 9,638 [10%]) and those with no evidence of treatment intensification during the observable follow-up period (n = 41,062 [44%]) were not included in further analyses. The median times from intensification to control were 20.0, 24.1, and 25.7 months, respectively, for the early, intermediate, and late intensification cohorts. After adjustment for baseline differences, the likelihood of attaining glycemic control was 22% and 28% lower for patients in the intermediate and late intensification groups, respectively, compared with those intensifying early (P < 0.0001). CONCLUSIONS: Earlier treatment intensification is associated with shorter time to subsequent glycemic control, independent of whether patients initiate first-line treatment with metformin or a sulfonylurea.
引用
- Desai U, Kirson NY, Kim J, et al. Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes. Diabetes Care. 2018. PMID: 30131396. doi:10.2337/dc17-0662
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。